经颅光生物调节疗法（tPBM）对美沙酮维持治疗患者减轻焦虑、抑郁和阿片类药物渴求的有效性：一项双盲、随机、对照试验。

The effectiveness of Transcranial Photobiomodulation therapy (tPBM) on reducing anxiety, depression, and opioid craving in patients undergoing methadone maintenance treatment: a double-blind, randomized, controlled trial.

作者信息

Helali Helya, Samani Nastaran, Tabeie Faraj, Eiliaei Shiva, Kheradmand Ali

机构信息

Department of Psychiatry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Psychiatry, School of Medicine, Behavioral Sciences Research Center of Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

BMC Psychiatry. 2025 Feb 3;25(1):94. doi: 10.1186/s12888-025-06555-3.

DOI:10.1186/s12888-025-06555-3

PMID:39901090

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11792211/

Abstract

BACKGROUND

The effects of tPBMT are from influencing compounds by triggering specific reactions, which stimulate Adenosine triphosphate biosynthesis and neurogenesis. According to these effects, tPBMT has been applied as a potential treatment for various neural-related diseases. The purpose of this study was to evaluate the impact of tPBMT on reducing anxiety, depression, and opioid craving in patients undergoing MMT.

METHODS

This randomized controlled clinical trial included two groups of substance-dependent patients undergoing MMT. They were randomly assigned to receive tPBMT or a sham tPBMT. The intervention group received PBM in the form of Light- Emitting Diodes (LEDs) for four minutes of light exposure at 810 nm wavelength producing 250 mW/cm when applied to 4 mm skin depth (totaling 60 J/cm) in both forehead locations. The levels of anxiety, depression, and opioid craving were compared between the two groups before and after the intervention, as well as at one-month and three-month follow-up assessments.

RESULTS

Both groups consisted of 32 (91.4%) males and 3 (8.6%) females, with the mean age of patients in the intervention group being 37.97 ± 10.58 years, and 39.66 ± 9.94 years in the control group (P = 0.495). There were no significant differences between the two groups in terms of depression, anxiety, and opioid craving scale scores before the intervention (p>0.05). However, the tPBMT group had statistically significant reductions in their scores compared to the sham tPBMT group. (p<0.05).

CONCLUSION

tPBMT led to significant improvements in anxiety, depression, and opioid craving among individuals in MMT, and these improvements were sustained at one month and three months after treatment, indicating a long-lasting positive effect.

TRIAL REGISTRATION

Trial registration: IRCT code: IRCT20210502051162N1, Approval ID: IR.SBMU.MSP.REC.1400.111, registered on 01.06.2021.

摘要

背景

经皮蓝光微秒治疗（tPBMT）的效果源于通过引发特定反应来影响化合物，这些反应会刺激三磷酸腺苷生物合成和神经发生。基于这些效果，tPBMT已被用作治疗各种神经相关疾病的潜在方法。本研究的目的是评估tPBMT对减少美沙酮维持治疗（MMT）患者焦虑、抑郁和阿片类药物渴望的影响。

方法

这项随机对照临床试验纳入了两组接受MMT的物质依赖患者。他们被随机分配接受tPBMT或假tPBMT。干预组接受以发光二极管（LED）形式的光生物调节（PBM），在两个前额部位以810纳米波长进行4分钟的光照，当应用于4毫米皮肤深度时产生250毫瓦/平方厘米（总计60焦耳/平方厘米）。在干预前后以及1个月和3个月的随访评估中，比较两组的焦虑、抑郁和阿片类药物渴望水平。

结果

两组均由32名（91.4%）男性和3名（8.6%）女性组成，干预组患者的平均年龄为37.97±10.58岁，对照组为39.66±9.94岁（P = 0.495）。干预前两组在抑郁、焦虑和阿片类药物渴望量表评分方面无显著差异（p>0.05）。然而，与假tPBMT组相比，tPBMT组的评分在统计学上有显著降低（p<0.05）。